TL;DR
Extracorporeal Membrane Oxygenation (ECMO), a life-saving technology for critically ill patients, significantly alters how the body processes drugs (pharmacokinetics or PK). This review highlights how ECMO circuits and patient physiology interact to change drug levels, often leading to sub-therapeutic or toxic effects, and emphasizes the critical need for better drug monitoring and individualized dosing strategies.
What Problem Does This Paper Address?
Critically ill patients often require complex pharmacotherapy to manage their conditions. When these patients also need Extracorporeal Membrane Oxygenation (ECMO) – a technology that supports failing lungs and/or hearts by oxygenating blood outside the body – managing drug therapy becomes exceptionally challenging. ECMO circuits, with their large surface areas and blood-contacting materials, can interact with drugs in unexpected ways, altering their absorption, distribution, metabolism, and excretion (pharmacokinetics, PK). This can lead to drugs not reaching effective levels (sub-therapeutic) or accumulating to toxic levels, potentially causing treatment failure or adverse events. Despite the increasing use of ECMO, especially during the COVID-19 pandemic, there's a significant lack of clear guidance on how ECMO specifically impacts the PK of commonly used drugs and how to adjust dosing accordingly. This paper aims to bridge that knowledge gap by reviewing the evidence on ECMO-induced PK alterations and suggesting monitoring strategies.
Methods
This paper is a comprehensive review of existing literature. The authors systematically analyzed published studies, case reports, and guidelines related to drug pharmacokinetics (PK) and pharmacodynamics (PD) in patients undergoing ECMO. They focused on identifying the mechanisms by which ECMO influences drug behavior, categorizing these influences by circuit-related factors (drug sequestration in the circuit, circuit priming, circuit age) and patient-related factors (altered physiology, organ dysfunction, fluid shifts). The review synthesizes data on the PK of various drug classes, including anticoagulants, antimicrobials, sedatives, and analgesics, commonly administered to ECMO patients.
Datasets
Not discussed in the paper. This is a review article, not an empirical study with its own dataset.
Key Insights and Ideas
- The ECMO Circuit as a "Drug Sponge": ECMO circuits, particularly the tubing and oxygenator membranes, can adsorb lipophilic (fat-soluble) and highly protein-bound drugs. This "sequestration" can lead to a significant loss of drug from the bloodstream, requiring higher initial doses.
- Patient Physiology is a Major Modifier: Beyond the circuit, the critically ill patient's own altered physiology (e.g., fluid shifts, organ failure, changes in protein binding) dramatically impacts drug distribution (volume of distribution, Vd) and clearance (CL). This can lead to either increased or decreased drug levels, depending on the drug and the specific patient factors.
- "One Size Fits All" Dosing is Dangerous: Standard dosing regimens for many drugs are often inadequate or even harmful in ECMO patients. The complex interplay of circuit and patient factors means that individualized dosing and frequent therapeutic drug monitoring (TDM) are essential.
- Anticoagulation is a Balancing Act: ECMO inherently increases the risk of both thrombosis (clotting) and bleeding. Managing anticoagulation requires careful monitoring of specific lab parameters (like ACT and aPTT) and consideration of patient-specific bleeding risks.
- Sedatives and Analgesics Need Special Attention: Lipophilic sedatives and analgesics (like propofol and fentanyl) are particularly prone to sequestration in ECMO circuits, often requiring higher doses to achieve adequate sedation or pain relief. Conversely, some drugs can accumulate due to altered patient metabolism or excretion.
Key Results
The review highlights that ECMO significantly impacts the PK of various drug classes:
- Anticoagulants: ECMO necessitates anticoagulation to prevent circuit clotting, but this increases bleeding risk. Monitoring is complex and varies between institutions.
- Antimicrobials: Many antibiotics, especially lipophilic ones, can be affected by sequestration in ECMO circuits. Studies show altered serum concentrations, with some patients failing to reach therapeutic targets.
- Sedatives and Analgesics: Lipophilic sedatives and opioids often require higher doses due to sequestration and altered patient physiology. Some drugs may accumulate, leading to prolonged sedation or respiratory depression.
- Specific Drug Examples:
- Piperacillin/Tazobactam: Studies suggest non-significant increases in clearance and Vd, but the protein-bound fraction can lead to underdosing.
- Vancomycin: While some studies show no significant PK changes, others indicate a longer time to reach target trough concentrations.
- Meropenem: Continuous infusion can lead to decreased clearance.
- Propofol: High lipophilicity leads to sequestration, often requiring higher doses.
Limitations and Future Work
The authors acknowledge that data on drug PK in ECMO patients are still scarce and often derived from small studies, case reports, or ex vivo experiments. Many studies do not measure "free" drug concentrations, which are more indicative of pharmacological activity. The review also points out the variability in ECMO circuit materials and patient populations, making direct comparisons challenging.
Future work should focus on:
- Conducting larger, prospective studies to establish evidence-based dosing guidelines for commonly used drugs in ECMO patients.
- Developing and validating more precise therapeutic drug monitoring strategies.
- Investigating the impact of different ECMO circuit components and configurations on drug PK.
- Understanding the PK/PD of novel drug classes in the ECMO setting.
- Exploring the role of patient-specific factors (genetics, organ function) in predicting drug responses during ECMO.
Summary updated